View text source at Wikipedia

Linaprazan

Linaprazan
Clinical data
Other namesAZD-0865
Legal status
Legal status
  • Investigational
Identifiers
  • 8-[(2,6-Dimethylphenyl)methylamino]-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC21H26N4O2
Molar mass366.465 g·mol−1

Linaprazan is an experimental drug for the treatment of gastroesophageal reflux disease (GERD). Unlike the proton-pump inhibitors (PPIs) which are typically used to treat GERD, linaprazan is a potassium-competitive acid blocker (P-CAB).[1][2] Linaprazan was developed by AstraZeneca, but it was not successful in clinical trials.[3]

The drug was then licensed to Cinclus Pharma,[4] which is now investigating linaprazan glurate, a prodrug of linaprazan which is expected to have a longer biological half-life than linaprazan itself.[4]

Chemical structure of linaprazan glurate

References

[edit]
  1. ^ Rawla P, Sunkara T, Ofosu A, Gaduputi V (December 2018). "Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?". World Journal of Gastrointestinal Pharmacology and Therapeutics. 9 (7): 63–68. doi:10.4292/wjgpt.v9.i7.63. PMC 6305499. PMID 30595950.
  2. ^ "Linaprazan". Inxight Drugs. National Center for Advancing Translational Sciences.
  3. ^ Tong A (4 March 2020). "Can reformulation of an AstraZeneca castoff rival Takeda's new heartburn drug? Here's a $26M bet on yes". endpts.com.
  4. ^ a b "Linaprazan glurate". Cinclus Pharma.